

**EMORY UNIVERSITY SCHOOL OF MEDICINE
CURRICULUM VITAE**

THERESA WICKLIN GILLESPIE

Office Address: Department of Surgery
Emory University
Surgical Oncology Suite C2004
1365C Clifton Rd., NE
Atlanta, GA 30322

Phone: 404-778-4617; 404-321-6111 x 4749

Fax: 404-417-5373

Citizenship: U.S.A.

CURRENT TITLES AND AFFILIATIONS

Academic Appointments

- Primary: Assistant Professor, Department of Surgery, Emory University
School of Medicine, Atlanta, GA 9/03 –
- Joint: Assistant Professor, Winship Cancer Institute, Emory University
School of Medicine, Atlanta, GA, 9/03 –
(Primary Appointment 10/98 - 9/03)
- Secondary: Clinical Associate, Nell Hodgson Woodruff School of Nursing,
Emory University, Atlanta, GA, 9/86-

Clinical and Research Appointments

Director, Division of Health Services Research, Veterans Affairs Medical Center, Atlanta,
Georgia, 2/1/04 -

Assistant Professor, Division of Hematology-Oncology, Department of Medicine and
Primary Care, and Division of Research, Veterans Affairs Medical Center, Decatur, GA,
3/01 -

Other Administrative Appointments

Associate Director, Winship Cancer Institute, Emory University, 7/07 -

PREVIOUS ACADEMIC AND PROFESSIONAL APPOINTMENTS

Instructor, Winship Cancer Center, Emory University School of Medicine, Atlanta, GA,
1/87-10/98

Instructor (joint), Dept. of Community & Preventive Medicine, Emory University School of Medicine, 6/91- 9/96

Director, Oncology Research, Spartanburg Regional Medical Center. and
Program Coordinator, Spartanburg Community Clinical Oncology Program
(CCOP), Spartanburg, South Carolina, 1/83-9/86

Instructor, Greenville Technical College, School of Nursing, SC, 11/85-2/86

Charge Nurse, Oncology Unit, Spartanburg Regional Medical Center, Spartanburg, SC,
8/81-11/82

Assistant Dean of Students, Agnes Scott College, Decatur, GA, 9/79-8/81

Director of Public Health Services and Health Education, Hôpital de Bibanga, East Kasai
Region; U.S. Peace Corps Volunteer, République du Zaire, Africa, 6/77-12/78

PREVIOUS ADMINISTRATIVE AND CLINICAL APPOINTMENTS

Associate Director and Chief, Scientific Affairs, Division of Health Services Research,
Veterans Affairs Medical Center, Atlanta, Georgia, 10/02 – 1/31/04

Member, Transfusion Medicine Program Faculty, Department of Pathology and
Laboratory Medicine, Emory University, 9/98 – 1/03

Director, Office of Research Support, Winship Cancer Institute, Emory University School
of Medicine, 1/97- 10/00

Director of Clinical Research and Education, Winship Cancer Institute, Emory University
School of Medicine, 9/86 - 10/2000

Assistant Laboratory Director, Transfusion Medicine and Tumor Immunology Research
Program Laboratories, Winship Cancer Institute and Department of Pathology and
Laboratory Medicine, Emory University, 2/98- 3/01; 1/02-1/03

Associate, Office of the Vice President for Research, Emory University, 9/98- 9/99

Associate Director, Winship Cancer Center, Emory University, 2/96- 1/97

Assistant Director, Winship Cancer Center, Emory University, 6/92-2/96

Safety Officer, Winship Cancer Center, Emory University School of Medicine, 9/87-8/95

LICENSURE/BOARDS

Registered Nurse, Georgia State License # R63317, Issued August 1981
Renewed through December 2009

National Certification in Oncology Nursing (OCN), May 1986 (Charter) by Oncology Nursing Certification Corporation (ONCC), Recertified 1990, 1994, 1998

EDUCATION

B.A. in Communication Studies/Interpersonal Communications, Minor: Chemistry;
College of Arts and Sciences, University of Florida, *Cum Laude*, 1976

M.A. in Health Education, Graduate School, University of Florida, 1977
Thesis: *Nonverbal Displays of Power by Medical Professionals*

B.S. in Nursing, Nell Hodgson Woodruff School of Nursing, Emory University, 1981

Ph.D., Division of Educational Studies, Graduate School of Arts and Sciences, Emory University, 1998. Specialty Tracks: Administration and Leadership in Higher Education; and Research Methodology.

Dissertation: *Comparison of Two Approaches Used in the Informed Consent Process in Research Involving Human Subjects as Measured by Patient Comprehension and Satisfaction*. Dissertation Committee Chair: Sandra Damico, PhD, Chair, Dept. of Educational Studies, Emory University.

COMMITTEE MEMBERSHIPS

National and International

Centers for Disease Control and Prevention
Abstract Review Committee, National Cancer Conference, 2007

Veterans Health Affairs
Abstract Review Committee, National VA HSR&D Meeting (2005, 2006, 2007)
National Committee for Quality Assurance (NCQA) Health Services Review
Committee (2001 –2003)

National Cancer Institute, Cancer Genetics Network
Education Committee (1998-2004)
Informed Consent Committee (1998-2004)

American Society of Clinical Oncology
Cancer Communications Committee (2001-2004)
Abstract Review – Patient Management Abstracts (ASCO National Meeting
2002)
Abstract Review – GYN Malignancies; Head & Neck Cancers;
Patient Management Abstracts (ASCO National Meeting 2003)
Abstract Review – Breast Cancer, GYN Malignancies, Sarcoma,
Leukemia, Lymphoma, and Transplantation (Adult) (ASCO National
Meeting 2004)
Expert Panel for Media Consultation (2005 – present)

Oncology Nursing Society – National

Member, National State of the Knowledge of Neutropenia Initiative & Conference (2005-2007)

Faculty, State of the Knowledge Regional Workshops (2005-2007)

Chair, National Conference on Hematological Toxicities (2003)

Local Arrangements Committee, ONS Congress (1998-99)

Educational Abstract Review Committee (1995)

Education Committee (1992, 1993)

Chair, Local Arrangements Committee, Fall Institute (1991)

American Association for Cancer Education

Local Arrangements Committee (1997)

American Association of Blood Banks

Abstract Review Committee, Annual Meeting (2002, 2003)

Abstract Review, Scientific Review Committee: Cellular Therapies (2004)

University of California San Francisco Medical Center and Affiliate Hospitals

Member, Expert Panel for Selection of Distinguished Nurse Award (2005, 2006)

Membership and Chairmanship of National Grant Review Committees

Scientist/Reviewer, Department of Defense, Congressionally Directed Medical Research Program (CDMRP), Breast Cancer Research Programs, Peer Review Panel, 2002 –2006

Co-Chair, Department of Defense, Congressionally Directed Medical Research Program (CDMRP), Breast Cancer Research Programs, Peer Review Panel, 2003 – 2004

Regional and State

Georgia Cancer Coalition

Committee for Statewide Infrastructure and Technology (2007 -)

Georgia Society for Clinical Oncology

Program Planning Committee (1991, 1992)

Executive Committee, GASCO/Georgia Cancer Coalition, Georgia Center for Education and Research (GA-CORE) (2002-2003)

Georgia Center for Cancer Research and Education (GA-CORE), Statewide Initiative for Cancer Research, Education and Training

Interim Board of Directors (2002 – 7/03)

Search Committee (2002 –2006)

Permanent Board of Directors (7/03 – 7/06)

Nominating Committee (2004)

Regulatory Committee (2004)

Research Committee (2004)

Co-Chair, Business and Grant Development (2005-2006)

Governor's Office – State of Georgia, Department of Human Resources
Review Committee, State Cancer Initiative (2000)

Atlanta-Birmingham Geriatric Research and Education Clinical Center
Member, Scientific Advisory Board, 2005 –

Institutional

Emory University

Operations Committee, Winship Cancer Institute (2007 -)

Core Directors Committee, Winship Cancer Institute (2007 -)

Basic Laboratory Research Committee, Winship Cancer Institute (2007 -)

Clinical Translational Science Award (CTSA) Initiative (2006)

Co-chair; Regulatory, Information Technology, and Research Ethics
Subcommittee

Interim Member, University Steering Committee for CTSA

Member, CTSA Education and Training Subcommittee for Residency
Research Education

Prostate Cancer SPORE, Winship Cancer Institute, Proposal Reviewer (2005)

Research Committee, Department of Surgery (2003 -)

Cancer Education Program Committee (1988-2000)

Oncology Nursing Task Force, School of Nursing (1990-present)

Population Science & Cancer Control Working Group (1990-present)

Tumor Site Clinical Working Groups, Winship Cancer Center (1991-present)

Cancer Committee, Emory University Hospital (1988-2002)

Search Committee, Nell Hodgson Woodruff School of Nursing, Endowed Chairs,
Oncology and Immunology (1999 –2002)

Clinical Research Review Committee, Winship Cancer Center

Co-Chair (1993-2000)

CRRC Subcommittee for Protocol Monitoring, Winship Cancer Center
(1993-2000)

Space Committee, Winship Cancer Center (1995-2000)

Shared Core Equipment Committee, Winship Cancer Center (1995-2000)

Task Force on Genetic Risk Assessment in Oncology (1996-2000)

Directors' Council, Winship Cancer Center (1996-2000)

Design Review Group, Comprehensive Cancer Center Construction Project, Office of the Dean, School of Medicine (1998 - 2000)

Core Advisory Committee, Comprehensive Cancer Center Construction Project, Office of the Dean, School of Medicine (1998 - 2000)

Winship Cancer Institute Operations & Financial Planning Subcommittee, Office of the Executive Vice-President for the Health Science Center (1999 - 2000)

 Chair, Subcommittee for Internal Operations (1999)

Program Planning Committee, Winship Cancer Center (1994-1996)

Clinical Executive Committee, Winship Cancer Center (1992-1996)

Cancer Center Planning Grant Committee (1992-1996)

University Health Services Committee (1991-1993)

Executive Committee, Winship Cancer Center (1987-1994)

Safety Committee, Winship Cancer Center (1987-1995)

Clinical Studies Review Committee, Winship Cancer Center (1987-1992)

Shared Facility Directors' Committee, Chair, Winship Cancer Center (1997- 99)

Clinical Working Group Chairs' Committee, Winship Cancer Center (1997-1999)

Cancer Survivors' Day Event Planning Committee (1990-1999); Chair 1993,'94

Atlanta Veterans Affairs Medical Center, Atlanta Georgia

Research & Development Committee -Institutional Review Board (2001-2006)

 Subcommittee for Review of Career Development Awards (2003–2005)

 Subcommittee for Review of Observational Studies (2006- present)

Cancer Committee (2001 – present)

Health Services Research and Development Division

 Chair, HSR&D Working Group (2002 – present)

 Chair, Pilot Grant Review Committee, HSR&D (2003 - present)

 Chair, Scientific Review Committee, HSR&D (2003 – present)

CONSULTANTSHIPS

Spartanburg Regional Medical Center, Community Clinical Oncology Program, Spartanburg, SC, 1987

Grady Memorial Hospital, Community Clinical Oncology Program, Atlanta, GA, 1990

Rockdale County Hospital, Cancer Program, Conyers, GA, 1991

Management Recruiters, Oncology Program Management, Charlotte, NC, 1991-1992

St. Francis Hospital, Cancer Program, Greenville, SC, 1992

Cancer Carepoint, Inc., Atlanta, GA, 1994

Piedmont Hospital Oncology Program, Atlanta, GA, 1995-1997

Huntsman Cancer Institute, University of Utah, NCI Grant, *"Intensive Course for Genetic Counselors and Oncology Nurses"*, (R. White, PI), 1996-1999

Baxter Corporation, Deerfield, IL, 1998

University of Miami, Sylvester Comprehensive Cancer Center, Clinical Research Program, Miami, Florida, 1999

Amgen, Inc., Thousand Oaks, CA, 1999 – 2004; 2006

Amgen Nurse Advisory Board, 2000 – 2001
Chair, 2002 - 2003

CancerData, Inc., Web Site and Information Technology Development, Atlanta, Georgia, 2000 - 2001

Amgen Anemia Management Institute, 2001 – 2002

Amgen Publications Advisory Board, 2001 – 2002

EmoryVision, Inc., Clinical Research Program, 2001 – 2003

Wyeth-Ayerst, Scientific Advisory Board, 2002

Georgia Society for Clinical Oncology-Georgia Cancer Coalition
Research Network Development Executive Committee, 2002

Genentech Oncology, Consultant, 2003-2006

National Oncology Alliance, Consultant, 2004

Pfizer Oncology, Consultant, 2004-2005

EDITORSHIPS AND EDITORIAL BOARDS

Editor

Journal of Clinical Oncology News Digest, 2002 - 2003

Consulting Editor

Gillespie TW. Editor. *Oncology Patient Education Resource Manual*, 2nd Edition, Aspen Publishers, Gaithersburg, MD.

Gillespie TW. Editor-in-Chief. *Anemia Management Institute*. HealthAnswers, Inc., Philadelphia, PA, 2004

MANUSCRIPT REVIEWER

Oncology Nursing Forum 1994 - present

Oncology Clinical Practice 1995 – present

Transfusion 2001- present

Cancer - 2002

Journal of General Internal Medicine 2004 - present

BMC Public Health 2006 – present

Journal of American College of Nutrition 2006-present

Monograph – Berger AM, Gallagher E, Meyer J. *Equal Treatment, Equal Benefit: Rethinking the Management of Anemia and Neutropenia in Older Adults with Cancer*.

Gillespie TW, Schulmeister L, Reviewers. Pittsburgh, PA: Oncology Education Services, 2002.

HONORS AND AWARDS

Georgia Nurses Association, 2005 Excellence in Research Award, May 2005

Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, Endowed Lectureship, Inaugural Lecture, *Genomics, Proteomics, and the Coming Revolution in Oncology Clinical Care*, New Brunswick, NJ, May 6, 2005

American Association for Cancer Research/Oncology Nursing Society (AACR/ONS) *Bench-to-Bedside Distinguished Lectureship*, Orlando, FL, April 29, 2005; Sponsored by the National Cancer Institute, R13

Who's Who in America® – 2006 Edition

Phi Kappa Phi Honor Society

Alpha Epsilon Delta Honor Society

Sigma Theta Tau International Nursing Honor Society

Who's Who in America, 2005

Who's Who in American Nursing 2000 - 2006

Who's Who of Women Executives, 1996

Champion of Hope Cancer Control Distinguished Service Award, American Cancer Society, DeKalb County Unit, 1993

Public Education Award, American Cancer Society, DeKalb County Unit, 1988, 1989, 1992

Volunteer of the Year, American Cancer Society, DeKalb Unit, 1988

Cynthia Mallory Award for Leadership in Nursing, Nell Hodgson Woodruff School of Nursing, 1981

MEMBERSHIP IN PROFESSIONAL SOCIETIES

American Society for Clinical Oncology

Cancer Communications Committee (2001-2004)
Abstract Review Committee, Annual Meeting, 2002, 2003, 2004
ASCO Expert Roster 2005-present

American Academy of Medical Administrators, Member

American College of Oncology Administrators, Member

American Association of Blood Banks

Abstract Review Committee, Annual Meeting, 2002, 2003, 2004

Association of Veterans Affairs Hematology Oncology

Oncology Nursing Certification Corporation

Oncology Nursing Society - National

Neutropenia National State of the Knowledge Committee, 2005-07
ONS Prevention and Detection Special Interest Group
ONS Management Special Interest Group
ONS Novel Therapies Special Interest Group
ONS Panel of Experts

Oncology Nursing Society - Metro Atlanta Chapter

Research Committee Chair (1/94-1/96)
ONS-President (1/91-1/92)
President-Elect, Membership Chair (1/90-1/91)
Secretary (1/88-1/90)
Board of Directors, Metro Atlanta Chapter ONS (1/88-1/96)

American Cancer Society - Georgia Division

Vice-President for Program Services, DeKalb Unit (1/92-8/94)
Chairman, Steering Committee (11/91-8/94)
Nursing Education Committee (3/90-11/91)
Chairman, Bylaws Committee (4/91-12/91)
Chairman, Public Education Committee (8/87-8/89)
Board of Directors, DeKalb County Unit (8/87-8/94)

American Public Health Association

American Society for Preventive Oncology

American Association for Cancer Education

The Users Network, Healthier People, The Carter Center of Emory University, Health Risk Appraisal Program

ORGANIZATION OF NATIONAL OR INTERNATIONAL CONFERENCES

Administrative Positions

Planning Committee, State of the Knowledge National Symposium on Neutropenia Management, January 20-21, 2006, Pittsburgh, PA

Chair, National Conference on Hematological Toxicities, October 9-12, 2003, Dallas, TX

Chair, National Curriculum Development Committee, Targeted Therapies, September 26-28, 2003, Chicago, IL

Oncology Nursing Society, Annual National Congress

Local Arrangements Committee (1998-99)
Session Chair (1990, 1991, 1994, 1996, 2001, 2003, 2005)
Pre-Congress Workshop Chair (2004)

Oncology Nursing Society, Annual National Institutes of Learning

Session Chair (1991, 1995, 2005)
Local Arrangements Committee, Chair (1991)

American Association for Cancer Education - Annual National Conference

Local Arrangements Committee (1997)

National Oncology Nursing Conference; Sponsor: Contemporary Forums, Dublin, CA.

Program Planning Chair (1998)
Program Planning Co-Chair (1991-1997; 1999-2007)
Regional Chair, Planning Committee (1990)

Georgia Society for Clinical Oncology - Annual Clinical Conference

Program Planning Co-Chair (1991)
Program Planning Committee (1992)

Oncology Education Services, Inc.

Planning Committee and Presenter: Dose Intense Chemotherapy: Evidence-Based Practice & Clinical Decision-Making - ONS Congress 2000

Planning Committee and Presenter: *Hematopoietic Growth Factors – Supportive Care for Chemotherapy-Induced Myelosuppression* – ONS Congress 2001

Chair, Planning Committee and Presenter: *Assessment and Management of Anemia and Neutropenia in Cancer Patients* – ONS Congress 2002

Chair, Planning Committee and Presenter: *Assessment and Early Intervention for Chemotherapy-Induced Neuropathy, Anemia, and Neutropenia* – ONS Congress 2003

Planning Committee and Presenter, *Targeted Therapies in Oncology*, National Institutes of Learning, November 7-8, 2003, Philadelphia, PA

Chair, Planning Committee and Presenter: *Angiogenesis Inhibitors in Solid Tumors* – ONS National Institutes of Learning, November 10-13, 2005, Phoenix, AZ

Sessions as Chair

Chair, National Conference on Hematological Toxicities, October 9-12, 2003, Dallas, TX

Chair, National Curriculum Development Committee, Targeted Therapies, September 26-28, 2003, Chicago, IL

Oncology Nursing Society, Annual National Congress
Session Chair (1990, 1991, 1994, 1996, 2001, 2003, 2005)
Pre-Congress Workshop Chair (2004)

Oncology Nursing Society, Annual National Institutes of Learning
Session Chair (1991, 1995, 2005)

RESEARCH FOCUS

My research is focused on decision-making and risk communications in cancer, including barriers to clinical trial accrual and informed decision-making by minority and older patients. Trials in clinical decision-making have examined provider adherence to evidence-based practice guidelines. National studies of public decision-making have investigated blood donor behaviors and motivations.

GRANT SUPPORT

Active Support

FEDERALLY FUNDED:

Principal Investigator, National Centers for Disease Control and Prevention, CDC IAA#TG-1, “Process Monitoring and Data Visual Display: Expectant Management of Patients Diagnosed with Early Stage Prostate Cancer as a Model”, 7/1/07 – 9/30/09, \$351, 545, 5% effort

Co-Investigator (J. Puskas, PI), U01 HL06005, “*Network for Cardiothoracic Surgical Investigations in Cardiovascular Medicine*”, 7/1/07-6/30/12, \$1,912,000

Principal Investigator, Department of Veterans Affairs, Veterans Health Administration TRP 03-210, “*Targeted Research Enhancement Award in Health Services Research*”, 8/1/04 – 7/30/08, \$500,000 (directs), 25% effort

Principal Investigator, National Centers for Disease Control and Prevention, CDC IAA#TG-1, “*Pattern of Follow-Up Among Prostate Cancer Survivors*”, 3/1/06 – 9/30/07, \$168,000, 10% effort

Principal Investigator, Veterans Health Administration, VISN 7 Oncology Consortium, “*Regional Assessment of Cancer Screening and Measurement of Clinical Practice Outcomes*”, 5/1/06 – 10/31/07, \$185,000, 5% effort

Co-Principal Investigator (M. Ribeiro, PI), NCI/Veterans Health Administration, “*Population Based Study of Care and Outcomes in Lung and Colorectal Cancer Patients (CanCORS)*”, 10/1/04 – 9/30/07, \$62,000, 5% effort

Co-Principal Investigator (V. Varma, Co-PI), National Centers for Disease Control and Prevention, CDC IAA#06-2, “*Impact of Improvements in Pathology Reporting on Quality of Oncology Care*”, 9/1/06 – 8/30/08, \$224,000, 5% effort

Co-Investigator (J. Lipscomb, PI), National Centers for Disease Control and Prevention, 3 U48 DP000043-02S1, “*Study of Determinants of Patient Drop-Out from Cancer Treatment and Follow-up*”, 10/1/05 – 9/30/07, \$306,373, 15% effort

Co-Investigator and Program Director (J. Mandel, PI), Georgia Cancer Coalition, “*Georgia State Cancer Cohort Study*”, 9/1/06 – 8/30/07 (pilot phase), \$1.1M, 25% effort

Co-Investigator (J. Guest, PI), National Centers for Disease Control and Prevention, CDC IAA, “*Colorectal Cancer Screening in HIV Infected Patients: A Feasibility Study*”, 10/1/06 – 9/30/07, \$25,000, 2% effort.

Co-Investigator (M. Wehbi, PI), National Centers for Disease Control and Prevention, CDC IAA, “*Improving the Quality of Colonoscopy in the VA: Pilot Study*”, 10/1/06 – 9/30/07, \$25,000, 2% effort.

PRIVATE FOUNDATION FUNDED:

None

PENDING:

Co-Investigator (S. Gabram-Mendola, PI), NIH/NCI, R25, “*Educational Intervention to Promote Breast Cancer Risk Assessment and Management in Georgia*,” 4/1/08 – 3/31/11, \$706,902, 10% effort.

PREVIOUS SUPPORT:

Co-Investigator (W. Zhou, PI), Department of Defense, PC040315 (W18XWH-05-1-0042), “*Study of Disease Progression in Prostate Cancer*”, 3/1/05-2/28/07, \$330,000, 5% effort

Principal Investigator, NCI 1K22CA87712, “*NCI Career Transition Development Award (K22)*”, 9/1/00-5/31/05, \$460,855, 75% effort

Principal Investigator, National Blood Foundation, (RFA-03), “*Study of the Blood Donation Decision*”, 3/1/00-7/30/04, \$242,928, 25% effort

Co-Investigator (W. Wood, PI, Subcontract with Duke University), National Cancer Institute (U24 CA78157), “*Carolina and Georgia Genetics Network Center*”, 3/1/98 - 6/30/2004, \$3,033,345, 5% effort

Co-Investigator, (M. Ribeiro, PI), Veterans Healthcare Administration, Geriatric Research, Education, & Clinical Center, “*Pilot Study of Elderly Patients Undergoing Pulmonary Rehabilitation Post-Surgical Resection for Lung Cancer*”, 3/1/02 – 3/31/04, \$50,000, 5% effort contributed

Consultant/Mentor, (M. Lee), NHLBI, “*Mentored Research Scientist Development Award for Minority Faculty (K01)*”, 6/1/01 – 5/31/04, \$324,000, 10% effort contributed

Co-Investigator, (J. Olson, PI), National Cancer Institute (U01 CA76605), “*Therapeutic Studies of Primary CNS Malignancies*”, 6/1/98 - 5/31/2003, \$52,000 (annual)

Co-Investigator, (W. Wood, PI), Eastern Cooperative Oncology Group (NCI CA-21115), “*Clinical Trials in Cancer*”, 5/1/88 - 4/30/03, \$64,000 (annual)

Co-Investigator, (C. Hillyer, PI), NHLBI (R01HL63366), “*Transfusion Transmission of Cell-Associated Infections*.” \$600,000, (2001-02), 15% effort

Co-Investigator, (C. Hillyer, PI) NHLBI (HL-02-001), “*Transfusion Medicine/Hemostasis Clinical Research Network Grant*”, \$1,270,589 (directs), 2002, 10% effort

Co-Investigator, (C. Hillyer, PI) NHLBI (R01HL-01-016), “*NHLBI Innovative Research Grant Proposal: PCR Screening for CMV in Umbilical Cord Blood Stem Cells*”, \$200,000, 4/1/02-10/31/02, 5% effort

Co-Investigator, (C. Hillyer, PI), American Red Cross, "*NAT Testing for CMV in Umbilical Cord Blood Stem Cells*", 9/1/01-10/1/02, \$75,000, 10% effort

Co-Investigator and Program Director (W. Wood, PI), American Cancer Society (IRG-182), "*Institutional Research Grant*", 10/1/99 - 9/30/01, \$120,000, 10% effort contributed

Co-Investigator, (I. Horowitz, PI), Gynecologic Oncology Group (NCI CA 27469), "*Clinical Trials in Gynecologic Malignancies*", 4/1/93 - 3/31/01, \$45,600 (annual)

Co-Investigator (C. Hillyer, PI), National Heart, Lung and Blood Institute (R01 HL53738), "*Effect of SIV Infection on Hematopoietic Stem Cells*," 4/1/96 - 3/31/2001, \$330,197, 5%

Co-Investigator (C. Hillyer, PI), National Heart, Lung and Blood Institute (R01 HL55176), "*Effect of Hematopoietic Cytokines on an Animal Model of AIDS*", 8/1/98-7/31/00, \$245,102, 10%

Co-Investigator, (T. Styblo, PI), NSABP (NCI U10-CA37377-08) "*Breast Cancer Prevention Trial & Breast/Colon Cancer Clinical Trials*", 12/1/91-12/30/00, \$40,000 (annual)

Co-Investigator, (J. Petros, PI), National Cancer Institute (R03 CA96-003), "*Women and Minority Recruitment to Clinical Trials: Survey of African-American Physicians and Patients*", 9/30/97-9/29/99, \$99,984, 5%

Co-Investigator & Program Director, (J.Petros,PI), National Cancer Institute (R21 CA95006), "*Developmental Grant for New Research Program in Prostate Cancer*," 9/1/95-8/31/99, \$764,328, 5%

Co-Investigator and Program Director (W. Wood, PI), American Cancer Society (IRG-182), "*Institutional Research Grant*", 10/1/95 - 9/30/00, \$150,000.

Co-Investigator and Program Director, National Cancer Institute (R25, J.W. Eley, PI), "*Cancer Education Program Grant*," 10/1/91-9/30/96, \$130,442, 5% effort.

Co-Investigator, National Cancer Institute (P20CA57133, H. Ozer, PI), "*Cancer Center Planning Grant*," 9/1/92-8/31/96, \$741,077, 10% effort

Co-Investigator, SWOG/NCI (S.D. Graham, PI), "*Prostate Cancer Prevention Trial*," 9/1/93-8/31/96, \$75,000.

Principal Investigator, Centers for Disease Control (312C-7801), "*Cancer Training for State Cancer Registry Staff*", 1/1/94-4/1/94, \$4960.

Principal Investigator, Centers for Disease Control #91062708, "*Breast and Cervical Cancer Training Course and Manual*," 6/91-6/92, \$19,343.

Principal Investigator, American Cancer Society Institutional Grant, IRG-182, "*Factors Affecting Patients' Knowledge and Decision-making Practices in Randomized Clinical Trials for Breast Cancer*," 11/1/91-12/31/92, \$8,000.

Co-Investigator, (J.McCullough, PI), National Cancer Institute (U10CA035119), “Community Clinical Oncology Program”, 9/1/83 – 7/1/86, \$450,000, 50% effort.

SERVICE CONTRIBUTIONS

- 1) Development, maintenance, and expansion of Cancer Center Clinical Research Program to provide investigators comprehensive services toward design and implementation of oncology clinical trials, including staff development, protocol and budget generation, patient/family education, regulatory affairs, data management and analysis; served as a resource to faculty, staff, and the community regarding access to clinical research and investigational therapies. In 1986 no organized clinical trial program in oncology existed at Emory University. At the close of this service in 10/2000 there was a comprehensive Clinical Trial Office with well-trained shared resources in research coordination and regulatory affairs. Emory University was ranked #3 among all NCI-sponsored Eastern Cooperative Oncology Group (ECOG) institutions for data quality, and the clinical trial unit had received numerous national awards for data quality and accrual. An average of more than 250 clinical trials were open; studies were conducted at all affiliate institutions; a cost-accounting system had been established and approved; data and regulatory monitoring system and database had been designed and implemented; specimen procurement for correlative science studies was in place; its annual budget was generally self-supporting through extramurally-supported trials (1986-2000).
- 2) Initiation and expansion of centralized Office for Research Support to provide grant application and preparation support; identification of funding opportunities related to cancer research in all areas; consultation to new, junior, and senior investigators regarding grant submission and management issues; and administration of the Winship Cancer Center’s multiple seed grant and fellowship programs and their review processes (1990-2000);
- 3) Development and enhancement of internal Clinical Trials Review and Monitoring System, to evaluate initial scientific merit, institutional prioritization, and resource utilization as well as ongoing progress toward reaching research goals and patient safety issues for all oncology-related trials (1993-2000). This system was granted NCI approval as part of the P30 site visit in 1996.
- 4) Development, maintenance, and expansion of research- and clinically-based database system used for patient, data, and protocol tracking, queries, and report generation, at Emory University (1995-2000) and VA (2000- present);
- 5) Directly responsible for generation of \$12.5M (directs) in successful NIH grants and contracts for institutional grants, training grants, program development, cancer center support, and clinical research (1986-2000);
- 6) Directly responsible for development of protocols and proposals generating \$3.4M in pharmaceutical industry funding in support of clinical trials (1986-2000);

- 7) Primary responsibility for the organization, coordination, and authorship of key components for the Cancer Center Support Grant (P30 CA71379) and oversight of planning and presentations for the NCI Site Visit as part of this application (1995-1996);
- 8) Initiation and development of Clinical, Translational, and Behavioral Research programs at the Veterans' Affairs Medical Center (2001 – present).
- 9) Initiation and development of Health Services Research and Development (HSR&D) program at Veterans' Affairs Medical Center, including faculty recruitment; generation of infrastructure and recruitment and training of core research service personnel; organization of working group; initiation and direction of pilot grant program; development of training initiatives for national VHA databases; and successful pursuit of national funding for programmatic development, resulting in a Targeted Research Enhancement Program (TREP) award in 2004. The TREP is the first Health Services Research grant awarded to the Atlanta VAMC in its history. This award is equivalent to an NIH center planning grant and provides programmatic support to develop an eventual national VA Center of Excellence in Health Services Research (2002–present). The VA HSR&D program has grown from zero dollars in extramural funding support and no core personnel in 2002 to \$4.75 Million in support and a comprehensive, multidisciplinary 9-member core service staff and faculty.

FORMAL TEACHING

Emory University School of Medicine:

Course Co-Coordinator and Faculty, Breast Cancer Didactic Weekly Conference, Division of Surgical Oncology, Department of Surgery, 2006 - 2007

Course Developer, Coordinator, and Faculty – Dept of Surgery
Research Training Curriculum for Divisions of Transplant, Gastrointestinal, General and Cardiovascular Surgery and Research Fellows, 2006

Course Developer, Coordinator, and Faculty - Dept of Surgery – Research Training Curriculum for Surgical Residents (1st and 2nd year), 2005 – present

Course Developer, Coordinator, and Faculty - Dept. of Orthopaedics: Resident Research Training Course
February 2005
January 2006
November 2006

Course Developer, Coordinator, and Faculty - Dept. of Physical and Rehabilitation Medicine: Resident Research Training Course
March 2005
February 2007

Hematology-Oncology Fellowship Training – 1998 – present

Director, Breast and Cervical Cancer Training Course - 1991, 1992, 1994

Lecturer, Physician's Assistant Program - 1992, 1993

Nell Hodgson Woodruff School of Nursing:

Course Coordinator, Faculty, and Research Supervisor
Honors Research, Undergraduate Program: 2005 - 2007

Lecturer, Undergraduate Program: 1987-1992; 2005 –
Co-Coordinator, Oncology & Immunology Graduate Course
Fall 2001, Spring 2002, Summer 2002

Lecturer, Advanced Practitioner Program, 2001 -present

Lecturer, Graduate Program, Oncology Nursing: 1987-1995, 2000 – present

Lecturer, Graduate Program: 2000 - present

Lecturer, Graduate Program, Theoretical Foundations:1991-1995

Graduate School of Arts and Sciences:

Lecturer, Policy in Higher Education: 1997 - 2000

Lecturer, Organizational Theory: 1997 - 2001

Atlanta Veterans Affairs Medical Center:

Clinical Research Training Program, 2002-2003

Course Developer, Coordinator, and Faculty

Clinical Investigator Training Program - Course plus Research
Application, for Clinical and Research Investigators and Fellows,
Biannually, 2004 – present

Course Developer, Coordinator, and Faculty

Introduction to and Application of VA and National Data Sets, 2007

Rollins School of Public Health

Lecturer, Health Policy and Management, HPM 591: 2007

SUPERVISORY TEACHING

Course Director and Research Supervisor, Honors Research, Nell Hodgson
Woodruff School of Nursing, Spring 2006, Fall 2006, Spring 2007

Students Supervised:

Emily Taylor, BSN Student

Joseph R. Garcia, BSN Student

Jenna Walker, BSN Student

Melissa Gordon, BSN Student

Christine Patton, BSN Student

Joyce Chowsanitphon, BSN Student

Regenia Faulcon, BSN Student

Karen Thomisee, BSN Student

Program Director, Graduate and Fellows Training Program in Health Services Research, jointly with Rollins School of Public Health, Emory University, 2004 –

Program Director, Summer Cancer Control Research Program (MD, MSN and MPH students), *R25 Cancer Education Grant*, Emory University: 1991- 1996

Clinical Preceptor, Graduate Nursing Program, Emory University: 1991-present

Preceptor, Undergraduate Program, Hughes Fellowship, Emory University: 1998, 1999

Mentor, NHLBI, “*Mentored Research Scientist Development Award for Minority Faculty (K01)*”, 6/1/01 – 5/31/04, Mark Lee, PhD

Residency & Fellowship Research Training, Emory University School of Medicine

Residents: Gordon Wotten, MD, Medicine, 2001
W. Eric Macleod, MD, Orthopaedics, 2005
Kelly Healy, MD, Surgery, 2006
Brett Switzer, MD, Orthopaedics, 2006-2007
Michael Schuler, MD, Orthopaedics, 2006-2007

Fellows: Lexy Kelley, MD, Pathology Fellow, 2002
Stephen Sgan, MD, Pathology Fellow, 2002
Milcah Larks, MD, Hematology Oncology Fellow, 2005 – 2006
Sudeshna Nandi, MBBS, Geriatric Fellow, 2005-2006

Summer Research Training Supervision, Transfusion Medicine, Emory University School of Medicine

Students: Jennifer N. Larson, Undergraduate, Johns Hopkins University
Catherine Jordan, Undergraduate, Agnes Scott College

Atlanta Veterans Affairs Medical Center, Health Services Research & Development

Resident: Elizabeth Tong, MD, MPH, Preventive Medicine, 2004

MD/PhD: Aki Morikawa, Dissertation Study, “*Case-Control Study Ch8p Allelic Imbalance & Prostate Cancer*”, 2005-06

Faculty: Verna Lamar Welch, PhD, Assistant Professor, Dept of Health Policy and Management, Rollins School of Public Health, 2004

Adam Herman, MD, Assistant Professor, Division of Geriatrics and Gerontology, Dept of Medicine, 2006 –

LECTURESHIPS, SEMINAR INVITATIONS, VISITING PROFESSORSHIPS

Director, Cancer Control Weekly Seminar, Emory University - 1991-1996

Director, Winship Cancer Center Seminar Series, Emory University - 1986-1994

Keynote Address: *The Importance of Dose in Chemotherapy Outcomes*, National Consensus Conference on Cancer Chemotherapy Dose and Dose Density, Phoenix, Arizona, April 16-18, 1999

Georgia Nurses Association Annual Meeting and Lectureship, "*Stem Cell Research: Hurdles, Hype, & Hope for Human Disease*", Atlanta, GA, February 12, 2004

Presenter, AACR/ONS *Bench-to-Bedside Distinguished Lectureship: Telomeres, Telomerase, & Clinical Implications for Cancer Care*. American Association for Cancer Research (AACR)/ Oncology Nursing Society.(ONS), Sponsored by the National Cancer Institute, April 29, 2005, Orlando, FL.

Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, Endowed Lectureship, Inaugural Lecture, *Genomics, Proteomics, and the Coming Revolution in Oncology Clinical Care*, New Brunswick, NJ, May 6, 2005

Neutropenia: National State of the Knowledge Symposium. Faculty Presenter and Program Planning Committee. Pittsburgh, PA, January 2006.

State of the Knowledge of Neutropenia Regional Workshops, Oncology Nursing Society, Nine Regional Workshops, Fall 2006 – Spring 2007

INVITATIONS TO NATIONAL OR INTERNATIONAL CONFERENCES

Vaccine Therapy in Oncology, Oncology Nursing Conference, Contemporary Forums, Atlanta, GA, October 1998

Cancer Metastases: Pathophysiology and Therapeutic Approaches, Oncology Nursing Conference, Contemporary Forums, Atlanta, GA, October 1998

Clinical Trials Review and Monitoring System: Principles, Pitfalls, and Paradigms, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, July 1999

Advances in Biological Therapy for Cancer: Progress in Vaccine and Gene Therapy, Oncology Nursing Conference, Contemporary Forums, San Antonio, TX, September 1999

New Approaches to Metastatic Disease, Oncology Nursing Conference, Contemporary Forums, San Antonio, TX, September 1999

Clinical Trials and Breast Cancer: Review of Recent Findings and Reduction of Breast Cancer Risk, Annual Breast Cancer Forum, Emory University, Atlanta, GA, September 30, 1999

Therapeutic Dose Intensity: Clinical Evidence-Based Review, Conference on Evidence-Based Decision-Making, Newport Beach, CA, February 11-13, 2000

Advances in Cancer Therapy 2000: Vaccines, Genes, and Biotherapy. Annual Meeting of Oncology Administrators and Nurse Managers, Hilton Head, SC, March 26, 2000.

Chemotherapy Dose and Dose Intensity, Oncology Nursing Society Congress, Ancillary Event, San Antonio, TX, May 11-14, 2000

Therapeutic Dose Intensity in Oncology, U.S. Oncology National Meeting, Marina Del Rey, CA, July 28, 2000

A Primer on Cancer Biology: Understanding Pathophysiology and Impact on Therapy, Oncology Nursing Conference, Contemporary Forums, San Francisco, CA, September 18-21, 2000

Metastatic Disease: Underlying Etiology and Therapeutic Approaches, Oncology Nursing Conference, Contemporary Forums, San Francisco, CA, September 18-21, 2000

Cancer Metastases: Understanding Pathophysiology and Therapeutic Strategies, Coordinator and Presenter, Oncology Nursing Society Congress, Instructional Session, San Diego, CA, May 2001

Cancer Biology and its Impact on Therapeutic Interventions, Oncology Nursing Conference, Contemporary Forums, Nashville, TN, October 2001

Novel Therapies for Metastatic Disease: Changing the Paradigm, Oncology Nursing Conference, Contemporary Forums, Nashville, TN, October 2001

Anemia Management Institute, Presenter & Moderator, St. Louis, MO, November 8, 2001

Advances in Cancer Therapy: Novel Pathways and Mechanisms of Action, Oncology Nursing Society Institutes of Learning, Institute of Novel Therapeutics, St. Louis, MO, November 2001

Preventing Errors in Oncology Medications, Presenter, Oncology Nursing Society Congress, Instructional Session, Washington, DC, April 2002

Management of Cancer Care in the Elderly Patient, Oncology Nursing Conference, Contemporary Forums, Minneapolis, MN, October 2002

Understanding Pathophysiology of Metastatic Disease and its Implications for Therapeutic Strategies, Oncology Nursing Conference, Contemporary Forums, Minneapolis, MN, October 2002

Pathophysiology of Cancer and Monoclonal and Radiolabeled Antibodies, in “Novel Therapies in Cancer”, Oncology Education Services, Newark, NJ, March 2003

Cancer Biology, Angiogenesis and Signaling Pathways: Carcinogenesis and Metastases. Coordinator and Presenter, Instructional Session, Oncology Nursing Society Congress, Denver, CO, May 2003.

Assessment and Early Intervention for Chemotherapy-Induced Neuropathy, Anemia, and Neutropenia. Coordinator and Presenter, Ancillary Session, Oncology Nursing Society Congress, Denver, CO, May 2003.

Unraveling the Complexities of Lymphomas, Oncology Nursing Conference, Contemporary Forums, Las Vegas, NV, September 2003

Lung Cancer: New Approaches to Diagnosis and Treatment, Oncology Nursing Conference, Contemporary Forums, Las Vegas, NV, September 2003

Novel Therapies: “Cancer Biology & Targeted Therapy” and “Tumor Immunology and Monoclonal Antibodies”, Duke University, Durham, NC, October 2003

Molecular Targets in Oncology, Ancillary Session, Institutes of Learning, Philadelphia, PA, November 2003

Neutropenia Prevention in Cancer Treatment, American Society of Hematology National Meeting, San Diego, CA, December 2003

Advances in Management of Chemotherapy-Induced Neutropenia, National Oncology Alliance Advisory Board, Ft. Lauderdale, FL, February 2003

Stem Cell Research: Hurdles, Hype, & Hope for Human Disease, Keynote Speaker, Georgia Nurses Association, Atlanta, GA, February 12, 2004

Risk Assessment and Proactive Management of Chemotherapy-Induced Anemia and Neutropenia, International Oncology Network Summit, Las Vegas, NV, February 2003

Novel Targeted Therapies and Nursing Implications, Metro Atlanta Oncology Nursing Society, Atlanta, GA, April 2004

Pathophysiology of Metastatic Disease and Implications for Therapy, Ohio Nursing Forum, Columbus, OH, April 2004

Advanced Cancer Biology, Coordinator and Presenter, Pre-Congress Workshop, Oncology Nursing Society Congress, Anaheim, CA, April 2004

Cancer, Aging, and Stress, First Annual Terry Symposium, Rollins School of Public Health, Emory University, Atlanta, Georgia, May 13-14, 2004

Cancer Biology and Targeted Therapies in Oncology, Kentucky Oncology Nurses Symposium, Lexington, KY, June 26, 2004

Overview of Cell Signaling and Proliferation, Oncology Nursing Conference, Contemporary Forums, Jersey City, NJ, September 2004

Pathophysiology of Metastatic Cancer and Novel Therapeutic Strategies, Oncology Nursing Conference, Contemporary Forums, Jersey City, NJ, September 2004

Genomics, Proteomics, and Cancer Care, Hackensack Medical Center, Hackensack, NJ, November 6, 2004

Advances in Targeted Therapy, Fox Chase Comprehensive Cancer Center Annual Conference, Philadelphia, PA, November 17, 2004

Evidence-Based Practice: Paradigms and Parameters. Columbus Clinical Oncology Conference, Columbus, GA, April 22, 2005

Bench-to-Bedside Distinguished Lectureship: Telomeres, Telomerase, & Clinical Implications for Cancer Care. American Association for Cancer Research (AACR) and Oncology Nursing Society, ONS Annual Congress, April 29, 2005, Orlando, FL.; sponsored by the National Cancer Institute

Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, Endowed Lectureship, Inaugural Lecture, *Genomics, Proteomics, and the Coming Revolution in Oncology Clinical Care*, New Brunswick, NJ, May 6, 2005

Genomics and Cancer, Oncology Nursing Conference, Contemporary Forums, Seattle, WA, October 12, 2005

Interpreting Pathology and Laboratory Data in Advanced Practice, Oncology Nursing Conference, Contemporary Forums, Seattle, WA, October 12, 2005

Genetics in Cancer: A Primer, Scripps Cancer Institute 25th Annual Symposium, San Diego, CA, October 25, 2005

Translational Research: Proteomics and Genomics for the Clinician, Chemotherapy Foundation Annual Symposium (Greenspan Meeting), New York, NY, November 5, 2005

Anti-Angiogenesis Therapy in Solid Tumors, Chair and Presenter, National Institutes of Learning, Oncology Nursing Society, Phoenix, AZ, November 10-13, 2005.

Targeted Therapies in Women's Cancers, Women's Cancer Conference, Arizona Comprehensive Cancer Center, Tucson, AZ, January 26-28, 2006.

Molecular Targets: Advancing Cancer Therapy, Scripps Cancer Center, Advanced Practice Oncology Conference, San Diego, CA, March 31, 2006

Cancer Genetics, Genomics, and Proteomics: A Primer for Cancer Care, Pensacola Tri-City Oncology Consortium, Pensacola, FL, May 20, 2006.

Monoclonal Antibodies: Mechanisms of Action and Potential Toxicities, Oncology Nursing Conference, Contemporary Forums, Las Vegas, NV, September 12-16, 2006

Pathophysiology of Metastatic Disease and Novel Treatment Strategies, Oncology Nursing Conference, Contemporary Forums, Las Vegas, NV, September 12-16, 2006

Interpreting Pathology and Laboratory Data in Advanced Practice, Oncology Nursing Conference, Contemporary Forums, Las Vegas, NV, September 12-16, 2006.

Signals and Targets in Cancer Therapy, Scripps Annual Oncology Conference, San Diego, CA, October 15-18, 2006.

Molecular Diagnosis of Cancer: From Tumor Markers to Gene Profiling, Scripps Annual Oncology Conference, San Diego, CA, October 15-18, 2006.

Management Issues with Targeted Therapies, Vanderbilt-Ingram Cancer Center Third Annual Fall Oncology Conference, Braselton, GA, October 27-29, 2006.

Risk Assessment, Risk Communications, and Informed Decision-Making in Cancer, Siteman Comprehensive Cancer Center Grand Rounds, Washington University, St. Louis, MO, December 11, 2006.

Genomics and Cancer: Personalized Medicine Becomes a Reality, Scripps Oncology Nurse Practitioner Conference, San Diego, CA, March 9, 2007.

Population Trends and Implications for Blood Donation: What Does the Future Hold for Blood Centers? Keynote Address, America's Blood Centers Annual Meeting, Washington, DC, March 26, 2007

BIBLIOGRAPHY

Published and Accepted in Peer-Reviewed Journals

Ades E, **Gillespie T**: Resolution of warts during IL-2 immunotherapy. *Pathobiology* 58(2):88-89, 1990.

Ades E, Bosse D, Orr S, **Gillespie TW**: Immune responses in humans while receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells: acute anergy to mitogens and recall antigens. *Pathobiology* 58(2):78-83, 1990.

Koretz MJ, Lawson DH, York RM, Graham SD, Murray DM, **Gillespie TW**, Levitt D, Sell KW: Randomized study of interleukin-2 alone vs. IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. *Arch Surg* 126:898-903, 1991

Simon DG, Eley JW, Greenberg RS, Newman N, **Gillespie TW**, Moore M: A survey of alcohol use in an inner city ambulatory care setting. *J Gen Int Med* 6:295-8, 1991.

Lee ME, Bucur SZ, **Gillespie TW**, Adams JW, Barker AT, Thomas EK, Roback JD, Hillyer CD: Recombinant human CD40 ligand inhibits SIV replication: A role for interleukin-16. *J Med Prim*, 28: 190-4, 1999.

Bucur SZ, **Gillespie TW**, Lee ME, Adams JA, Bray RA, Villinger F, Winton EF, Novembre F, Ansari AA, Hillyer CD: Hematopoietic response to lineage non-specific (rIL-3) and lineage-specific (rhG-CSF, rhEpo, rhTpo) cytokine administration in SIV-infected rhesus macaques is related to stage of infection. *J Med Primatology*, 29: 47-56, 2000.

Gillespie TW: Chemotherapy Dose and Dose Intensity: Analyzing Data to Guide Therapeutic Decisions. *Onc Nurs Forum* 28 (2): 5-10, 2001.

Gillespie TW: Effects of Anemia of Cancer on Clinical and Quality of Life Outcomes. *Clinical Journal of Oncology Nursing* 6: 206-211, 2002

Gillespie TW: Hematopoietic Growth Factor Combinations: How Do We Address Multiple Concurrent Hematologic Toxicities ? *Oncology Supportive Care Quarterly* 1 (3): 26-33, 2003.

Gillespie TW. Anemia in Cancer: Therapeutic Implications and Interventions. *Cancer Nursing*, 26 (2): 119-128, 2003.

Staley CA, Harris WB, Landry J, Small W, Kooby D, **Gillespie TW**, Meyers M, Bhalla K. Neoadjuvant induction chemotherapy followed by chemoradiation: A phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies. *Surg Oncol Clin N Am* 13: 697-709, 2004.

Ropka ME, Padilla G, **Gillespie TW**. Risk modeling: Applying evidence-based assessment in oncology nursing practice. *Onc Nurs Forum* 32:49-56, 2005.

Roback JD, Caliendo AM, Newman JL, Sgan S, Saakadze N, **Gillespie TW**, Lane TA, Kurtzberg J, Hillyer CD. Detection of cytomegalovirus DNA in cord blood from cytomegalovirus-negative mothers. *Transfusion* 45: 1722-28, 2005.

Gillespie TW. Nursing Interventions in the Management of Patients With Cancer-Associated Thrombosis. *Seminars in Oncology Nursing* 21 (Suppl 1): 50-59, 2005.

Nirenberg A, Bush AP, Davis A, Friese C, **Gillespie TW**, Rice D. Neutropenia Management: A White Paper. Part I. *Onc Nurs Forum*, 33: 1193-1201, 2006.

Nirenberg A, Bush AP, Davis A, Friese C, **Gillespie TW**, Rice D. Neutropenia Management: A White Paper. Part II. *Onc Nurs Forum*, 33: 1202-1208, 2006.

Editorials

Gillespie TW. Editorial. The "crisis" in blood donation...science. *Transfusion* 45: 128-129, 2005.

Manuscripts Submitted

Gillespie TW, Steeh CG, Burrige AB. National study of blood donation decision-making by non-donors. *Transfusion* (in revision).

Gillespie TW, Newman JL, Burrige AB. National study of blood donor decision-making: current and lapsed donors. *Transfusion* (in revision).

MacLeod EW, Labib S, Xerogeanes JW, **Gillespie TW**, Viehe T. Isolated meniscal injury and its association with femoral articular lesions. (Submitted).

Gillespie TW. Prospective analysis of barriers to oncology clinical trials. *J Clin Oncol* (in review).

Bucur SZ, **Gillespie TW**, Roback JD, Lee ME, Adams JA, Bray RA, Villinger F, Winton EF, Novembre F, Ansari AA, Hillyer CD: Differential hematopoietic responses to rhFlt-3 ligand in SIV infected rhesus macaques: early vs late stage administration. *Am J Hematology* (submitted).

Gillespie TW: Comparison of Two Approaches Used in the Informed Consent Process in Oncology Clinical Trials. *J Clin Onc* (submitted).

Lee ME, Adams JWE, Barker AT, **Gillespie TW**, Ansari AA, Hillyer CD: Extracellular RANTES depletion by rhesus cytomegalovirus infected fibroblasts: Support for the presence of rhesus US28. *J Gen Virology* (submitted).

Lee ME, Bucur SZ, **Gillespie TW**, Thomas EK, Ansari AA, Hillyer CD: Trimeric recombinant CD40 ligand administration in SIVmac infected rhesus macaques. *AIDS* (submitted)

Review Articles

Gillespie TW, Hillyer CD: Peripheral blood stem cells for bone marrow reconstitution: Mobilization and collection strategies. *Transfusion* 36:611-624, 1996.

Hillyer CD, Lankford KV, Roback JD, **Gillespie TW**, Silberstein LE. Transfusion of the HIV seropositive patient: Immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. *Transfusion Medicine Reviews* 13:1-17, 1999.

Gillespie TW & Hillyer CD : Blood donors and factors impacting the blood donation decision. *Transfusion Medicine Reviews* 16: 115-130, 2002.

Book Chapters

Gillespie TW. Biology of cancer. In York, G.Y. (Ed.), *Oncology Nursing Care*, San Diego: Western Schools, 1995.

Gillespie TW. Overview of cancer therapy. In York, G.Y. (Ed.), *Oncology Nursing Care*, San Diego: Western Schools, 1995.

Gillespie TW. Cancer therapy: Surgery. In York, G.Y. (Ed.), *Oncology Nursing Care*, San Diego: Western Schools, 1995.

Gillespie TW. Cancer therapy: Chemotherapy. In York, G.Y. (Ed.), *Oncology Nursing Care*, San Diego: Western Schools, 1995.

Gillespie TW. Unproven methods of cancer treatment. In York, G.Y. (Ed.), *Oncology Nursing Care*, San Diego: Western Schools, 1995.

Gillespie TW. Oncological emergencies. In York, G.Y. (Ed.), *Oncology Nursing Care*, San Diego: Western Schools, 1995.

Frost SF, and **Gillespie TW.** Organizations, Culture, and Teams: Links Toward Genuine Change. In Frost, S.F. (Ed.), *Using Teams in Higher Education: Cultural Foundations for Productive Change*, New Directions for Institutional Research, San Francisco: Jossey-Bass, Inc., 1998.

Gillespie TW and Hillyer CD. Granulocytes. In Hillyer, C.D., Jeffries, L., Silberstein, L.E., and Stobl, F. (Eds.), *Handbook of Transfusion Medicine*, Philadelphia, PA: Academic Press, 2001.

Gillespie TW. Surgical Therapy in Cancer. In Yarbro CH, Frogge M, and Goodman M (Eds). *Cancer Nursing*, 6th Edition. Boston, MA., Jones and Bartlett, pp. 212-229, 2005.

Monographs

Berger AM, Gallagher E, Meyer J. *Equal Treatment, Equal Benefit: Rethinking the Management of Anemia and Neutropenia in Older Adults with Cancer.* **Gillespie TW**, Schulmeister L, Reviewers. Pittsburgh, PA: Oncology Education Services, 2002.

Gillespie TW. Implementation of the NCCN Practice Guidelines: Anemia and Neutropenia. *Advanced Studies in Nursing Monograph Series*, 3(9): 300-309, Nov. 2005.

Books Edited and Written

Gillespie TW. Editor. *Oncology Patient Education Resource Manual*, 2nd Edition, Aspen Publishers, Gaithersburg, MD, 2001.

Manuals, Videos, Computer Programs, Teaching Aids

Gillespie TW, Ed. *Manual for Breast and Cervical Cancer Screening Programs.* U.S. Centers for Disease Control, Atlanta, 1992.

Abstracts

Gillespie T, Simon D, Eley W: Patterns of tobacco use and health beliefs among urban blacks. *Onc Nurs Forum Supp* 15(2), 1988.

Gillespie T, Sullivan S, Kimbell P: Design and evaluation of a preventive oncology program for employees. *Journal of Cancer Education* 3(4), 1988. Oral Presentation.

Gillespie T: Analysis of knowledge deficits made to a University cancer information service. *Onc Nurs Forum Supp* 16(2), 1989. Oral Presentation.

Ades E, Bosse D, Orr S, **Gillespie T**: In vivo and in vitro evaluation of immune function of patients receiving either IL-2 or IL-2 and LAK: rapid induction of anergy as a result of proliferation of cells with immune dysfunction. Abstract presented to the American Society for Clinical Oncology, May, 1989.

Koretz M, Murray D, Graham S, Lawson D, York R, **Gillespie T**, Orr S, Eagle K, Hart K, Levitt D, Sell K: A randomized study of interleukin-2 alone vs IL-2 lymphokine-activated killer (LAK) cells for treatment of melanoma and renal cell cancer. Abstract presented to the Society for Surgical Oncology, May 1989.

Ades E, Bosse D, Orr S, **Gillespie T**: Induction of immune response anergy in patients receiving either IL-2 or IL-2 and LAK. Abstract presented to the Society for Biological Therapy, November, 1989.

Gillespie T: Redefining the "fine line" - addressing knowledge deficits regarding unproven methods versus investigational therapies. *Onc Nurs Forum Supp* 17(2), 1990. Oral Presentation.

Styblo TM, Koretz MJ, Lawson DH, York RM, Graham SD, **Gillespie TW**, Levitt D, Sell KW: Phase II study of rIL-2 and IFN-alpha for melanoma, colorectal cancer, and renal cell cancer. Poster presentation to the Society for Biological Therapy, November 1991.

Gillespie TW, Sell KS, Levitt D: Nursing management of the patient on a clinical trial receiving biological response modifiers (BRM's) in the outpatient setting. *Onc Nurs Forum Supp* 17(2), 1990.

Gillespie TW, Beisel M, Eagle K: Implementing Phase II clinical trials: Taxol as a model. *Onc Nurs Forum* 18(2), 1991. Oral Presentation.

Gillespie TW: Primary brain tumors: they're not just for neurosurgeons anymore. *Onc Nurs Forum*, 19(2), 1992. Oral Presentation.

Gillespie TW: Intraarterial chemotherapy: three regional approaches and nursing implications. *Onc Nurs Forum* 19(2), 1992. Oral Presentation.

Gillespie TW: Taxol: Past experiences, current controversies, future directions. *Onc Nurs Forum* 21(2), 1994. Oral Presentation.

Gillespie TW. Study of knowledge levels of patients with early stage breast cancer. Poster presentation to the Oncology Nursing Society Annual Congress, May 1994.

Gillespie TW. Conducting oncology clinical research in a managed care environment: Is it possible? Poster presentation to the Oncology Nursing Society Annual Congress, May 1995.

Gillespie TW. Maintaining credibility in oncology clinical trials and practice in the aftermath of scientific misconduct on a national level. Poster presentation to the Oncology Nursing Society Annual Congress, May 1995.

Gillespie TW. Developing a breast health center: Plans, process, and evaluation. Oncology Nursing Society Annual Congress, May 1995. Oral Presentation.

Hillyer CD, Lackey DA, Bucur SZ, Adams JW, Lee ME, Buccolo LS, Trainor LD, **Gillespie TW**, Villinger F, Mayne A, Bray RA, Winton EF, Ansari AA. Studies of the effects of recombinant human (rh) and rhesus (rr) cytokines on hematologic and virologic parameters in a cohort of SIVmac239 infected macaques and in vitro. Presented to 14th Annual Symposium on Nonhuman Primate Models for AIDS, Portland, OR, 1996.

Bellamy LM, Mannion-Wood AM, **Gillespie TW.** Reducing Thrombocytopenic Complications in Oncology: Nursing Implications of Thrombopoietin. Presented to the Oncology Nursing Society Congress, New Orleans, May 1997.

Gillespie TW, Selvidge LS. Developing an Oncology Genetic Risk/Counseling Program: Plans, Process, and Evaluation. *Ons Nurs Forum* 24 (2), 1997. Oral Presentation.

Billingsley J, **Gillespie TW**, Olson JJ. Hyperthermia with Brachytherapy in the Treatment of Progressive Malignant Brain Tumors: Nursing Assessment. Oncology Nursing Society Congress, New Orleans, May 1997.

Hill CS, Olson JJ, **Gillespie TW.** Nursing Implications of Suramin Treatment. Presented to the Oncology Nursing Society Congress, New Orleans, May 1997.

Jones EM, McGuire WP, **Gillespie TW.** Topotecan as Second-Line Chemotherapy for Platinum Resistant Ovarian Cancer Patients: Nursing Care Implications. Presented to the Oncology Nursing Society Congress, New Orleans, May 1997.

Billingsley J, **Gillespie TW**, Olson JJ. Gene Therapy: The Leading Point on the Cutting Edge of New Treatment Modalities for Malignant Brain Tumors. Oncology Nursing Society, San Francisco, May 1998. Oral Presentation.

Jones EM, **Gillespie TW.** Multidrug Resistance and the Use of Chemosensitizers. Oncology Nursing Society, San Francisco, May 1998. Oral Presentation.

Shulman C, **Gillespie TW.** Toxicity Profile of Liposomal Doxorubicin in Renal Cell Carcinoma. Presented to the Oncology Nursing Society, San Francisco, May 1998.

Gillespie TW. Use of a Two-Part Consent Form to Improve Comprehension of Informed Consent in Clinical Research Trials. Presented to the Oncology Nursing Society, San Francisco, May 1998.

Bucur SZ, **Gillespie TW**, Roback JD, Lee ME, Adams JW, Bray RA, Villinger F, Winton EF, Novembre F, Ansari AA, Hillyer CD. Bone marrow response to rIL-3 administration in SIV infected rhesus macaques in relation to stage of infection. 16th Annual National Symposium on Nonhuman Primate Models for AIDS, Atlanta, GA, October 1998.

Bucur SZ, **Gillespie TW**, Roback JD, Lee ME, Adams JW, Bray RA, Villinger F, Winton EF, Novembre F, Ansari AA, Hillyer CD. Hematopoietic response to rhG-CSF administration during early versus late stage SIV infected rhesus macaques. 16th Annual National Symposium on Nonhuman Primate Models for AIDS, Atlanta, GA, October 1998.

Villinger F, Chikkala NF, Brar SS, Bucur SZ, Lee ME, **Gillespie TW**, Adams JA, Bostik P, Mayne AE, Dailey P, Novembre FJ, Ansari AA, Hillyer CD. IL-12 responses in vivo are lost during disease progression in SIV infected macaques. 16th Annual Symposium on Nonhuman Primate Models for AIDS. Atlanta, GA, October 1998.

Bucur SZ, **Gillespie TW**, Lee ME, Adams JW, Bray RA, Villinger F, Winton EF, Novembre F, Ansari AA, Hillyer CD. Hematopoietic reserve and mobilization potential, and viral load during early and late stage SIV. *Blood* 92 (10S): 381a, 1998.

Bucur SZ, **Gillespie TW**, Lee ME, Adams JW, Bray RA, Villinger F, Winton EF, Novembre F, Ansari AA, Hillyer CD. Bone marrow response to exogenously administered cytokines in a cohort of rhesus macaques infected with monocytotropic strain, SIVmac239 17E. *Blood* 92 (10S): 380a, 1998.

Lee ME, Adams JW, Bucur SZ, **Gillespie TW**, Barker A, Thomas E, Hillyer CD: The antiviral activity of recombinant CD40L: A role for caspase-3 processing of interleukin-16. 6th Congress on Retroviruses and Opportunistic Infections, Feb.1999, Chicago, IL.

Lee ME, Adams JW, Barker AT, Gillespie TW, Cruikshank WW, **Hillyer CD**: The role of MAPK kinases in interleukin-16-mediated inhibition of SIVmac239 replication. *J Hum Virol* 2 (4): 231; (abstract # 327) 1999.

Petros JA, Issa MM, Keane TE, Edwards B, Tarver E, Bennett J, **Gillespie TW**, Burnett M. Prostate cancer awareness and screening behavior: African-American physicians. American Urological Association, 1999 Annual Meeting, Dallas, TX.

Gillespie TW. New approaches to cancer therapy- Angiogenesis inhibitors: Thalidomide as a model. Oncology Nursing Society, May 2000, San Antonio, TX. Oral Presentation.

Gillespie TW, Harmon MP. Outcomes of randomized study of two approaches to informed consent in oncology clinical trials. Oral Presentation. *Proceedings of the American Society of Clinical Oncology*, 19: 435a, 2000.

Gillespie TW. Preventing errors in chemotherapy orders for clinical trials: Evaluation of program compliance and outcomes. Oncology Nursing Society, May 2001, San Diego, CA. Oral Presentation.

Hill CH & **Gillespie TW**. Carboxyamidetriazole (CAI), an oral antiangiogenic agent: Nursing implications of Phase II clinical trials. Oncology Nursing Society, May 2001, San Diego, CA. Oral Presentation.

Lee ME, Adams JW, Barker AT, **Gillespie TW**, Hillyer CD: Modulation of RANTES Concentration by Rhesus CMV Infection of Fibroblasts: A role for US 28? *18th Annual Symposium on Nonhuman Primate Models for AIDS*. Madison, WI, September 2001.

Gillespie TW, Steeh CG, Hillyer KL, Strong M, Hillyer CD: National Study of Blood Donation Decision-Making by Non-Donors. *Blood* 98: 61a, 2001.

Gillespie TW. Prospective Analysis of Barriers to Clinical Trial Accrual. Oral Presentation. *Proceedings of the American Society of Clinical Oncology*, 21: 247a, 2002 (#987).

Steeh CG, Ling-Chard C, **Gillespie TW**. Measuring Social Capital: The Case of Blood Donations. American Association for Public Opinion Research, May 2002.

Gillespie TW, Newman JL, Bellamy M, Hillyer KL, Strong M, Hillyer CD. National Study of Blood Donation Decision-Making: Current and Lapsed Donors, *Transfusion*, 42 (9 Supplement): 122S, 2002.

Roback JD, Kelley L, Saakadze N, **Gillespie T**, Hillyer CD. Kinetics of Peripheral Blood Murine Cytomegalovirus (MCMV) Viremia Following Infection: Implications for a Mouse Model of Transfusion-Transmitted CMV (TT-CMV), *Transfusion*, 42 (9 Supplement): 30S, 2002.

SL Sgan, **TW Gillespie**, JD Roback, AM Caliendo, J Kurtzberg, CD Hillyer . Nucleic Acid Testing (NAT) (PCR) for Cytomegalovirus (CMV) in Umbilical Cord Blood Plasma (UCP) and Stem Cell Components (UCBSC). *Transfusion*, 42 (9 Supplement): 29S, 2002.

SL Sgan, **TW Gillespie**, A Caliendo, JD Roback, TA Lane, CD Hillyer. Predictive Value of Nucleic Acid Testing (NAT) for Cytomegalovirus (CMV) in Maternal Donors of Umbilical Cord Blood Stem Cell (UCBSC) Components by Serostatus. *Transfusion*, 42 (9 Supplement): 29S, 2002.

TW Gillespie, LM Bellamy, P McDaniel, D Glenn, A Allen, WB Harris, M Shumate, D Peteet, J Jacobs, MJ Ribeiro. Prospective Analysis of Barriers to Enrollment on Oncology Clinical Trials – Comparison of Veterans Affairs and University Medical Centers. 7th Annual VA National Cancer Symposium, Washington, DC, October 2002, Plenary Session.

Roback JD, **Gillespie TW**, Kelley V, Saakadze N, Hillyer CD. Transfusion-transmitted CMV infection in a mouse model: High load of latent virus required for transmission. *Blood*, 100, 25a (#82), 2002. Plenary Session.

Gillespie TW, Bellamy LM, Harris WB, Peteet D, Wotton, G, Shumate M, Ribeiro MJ. Evidence-Based Decision-Making for Elderly Patients Undergoing Cancer Therapy: A Feasibility Study. *Proceedings of the American Society of Clinical Oncology*, 22: 545, 2003, (#2191).

Anderson KA, and **Gillespie TW**. Ageist Attitudes Among Nurses: Implications for Long-Term Nursing Care of Elder Clients with Cancer. *Oncology Nursing Forum*, 31, 459 (#274), 2004.

Gillespie TW, Patterson H, Harris WB, Shumate M, Nadella P, Jacobs J, Ribeiro MJ. Improving clinical outcomes in elderly oncology patients. *Proceedings of the American Society of Clinical Oncology*, 23: 535 (6075a), 2004.

Ribeiro, MJ, Patterson H, Shumate M, Harris WB, Jacobs J, Nadella P, **Gillespie TW**. Compliance with guidelines for elderly patients undergoing cancer therapy. *Proceedings of the American Society of Clinical Oncology*, 23: 553 (6148a), 2004.

Varma V, Harrell R, **Gillespie TW**. Structured pathology reporting. Oral Presentation. International Academy of Pathology, Brisbane, Australia, October 2004.

Gillespie TW, Newman JL, Burrige AB. Comparison of Blood Donor Decision-Making by Center Type: American Red Cross Blood Centers (ARC) and Community Blood Centers (ABC). Oral Presentation, American Association of Blood Banks Annual Meeting, Baltimore, MD, October 2004.

Gillespie TW, Lipscomb J, Ribeiro MJ. Use of VA Central Cancer Registry (VACCR) Data as a Cancer Research Tool. Oral Presentation. Association of Veterans Affairs Hematology Oncology Annual Meeting, Cincinnati, OH, October 13-15, 2006.

Rice RD, Nirenberg A, Davis A, Friese C, **Gillespie TW**. Neutropenia Management: State of the Knowledge. Oncology Research Conference. Oral Presentation. Oncology Nursing Society Research Conference, Hollywood, CA, February 8-10, 2007.

Lipscomb J, **Gillespie TW**, Ward KC, Goodman M. Early termination of adjuvant therapy in breast and colorectal cancers. American Society of Clinical Oncology Annual Meeting, June 1-5, 2007, Chicago, IL. *Proc ASCO*

Lipscomb J, **Gillespie TW**, Ward KC, Goodman M. Determinants of patient dropout from cancer therapy. Academy Health National Meeting. June 3-5, 2007, Seattle, WA. *Accepted for Poster Presentation*

Gillespie TW, KC Ward, M Goodman, LC Richardson, LA Pollack, J Lipscomb. Early Termination of Adjuvant Therapy for Breast and Colorectal Cancers. Centers for Disease Control Cancer Conference, August 13-16, 2007, Atlanta, GA. *Accepted for Poster Presentation*

KC Ward, **TW Gillespie**, M Goodman, P Roberts, LC Richardson, LA Pollack, J Lipscomb. Completion of Radiation Treatment by Cancer Patients in Rural Georgia. Centers for Disease Control Cancer Conference, August 13-16, 2007, Atlanta, GA. *Accepted for Poster Presentation*

M Goodman*, **TW Gillespie**, KC Ward, D Fletcher, P Roberts, LA Pollack, LC Richardson, J Lipscomb. Creating a Research Network for Population-based Studies in Rural Georgia. Centers for Disease Control Cancer Conference, August 13-16, 2007, Atlanta, GA. *Accepted for Poster Presentation*

Stephen Lau MD, **Theresa Gillespie PhD**, Joseph Lipscomb PhD, Ken Gerlach MPH, Missy Jamison MPH, Vijay Varma MD. Anatomic Pathology Reporting System for the 21st Century. College of American Pathology Annual Meeting, September 2007.

Invited Publications

Gillespie TW. "Molecular Targets for Treating Colorectal Cancer." In *Novel Approaches to Patient Care*, Wood, L., Chief Ed. Pittsburgh, PA: Oncology Education Services, Inc., 2004.

Gillespie TW. Hematopoietic Growth Factor Combinations: How Do We Address Multiple Concurrent Hematologic Toxicities? *Anemia Management Institute*, 2: 6-10, 2002.

Gillespie TW. Evidence-Based Practice and Oncology Care for the Elderly. *Metro Atlanta Chapter Oncology Nursing Society Newsletter*, December 2001.

Gillespie TW. Genomics, Proteomics, and the Impact on Cancer Therapy. *Metro Atlanta Chapter Oncology Nursing Society Newsletter*, June 2001.

Gillespie TW. Lung Cancer: A Women's Health Issue No One Talks About. *Oncology Update* 1999.

Gillespie TW. Thrombopoietin and Thrombocytopenic Complications of Cancer Therapy. In *Biotherapy: Considerations for Oncology Nurses*, 3(2): 8-10, 1998.

Gillespie TW. Thrombopoietin: The Last Growth Factor? In *ONS Newsletter*, Biotherapy Interest Group, Fall 1997.

Gillespie TW. Chemoprevention: Building a Better Mousetrap? *Prevention/Early Detection*, 4(3), 1993.

Gillespie TW. Breast Cancer Screening Update. *The Emory Report*, 46 (7), October 5, 1993.

Gillespie T. Immunotherapy: magic bullet or mighty myth? *In Touch* 9(4):4-5, 1989.